Click here to view the United Healthcare (UHC) Medical Policy Updates » December 2024 United…
BCBS Arizona Medical Policy Updates – November 2024
Stay ahead in medical policy monitoring and tracking with personalized reports and a real-time dashboard tailored to specific products, procedures, or codes. For those seeking a more impactful solution than Policy Reporter, our platform delivers comprehensive data analytic tools, user-friendly dashboard and collaboration features, client-focused solutions, and real-time email alerts.
Schedule a demo to see how our focused reports save time and provide actionable insights for your reimbursement and commercialization efforts.
Click here to view the Blue Cross Blue Shield BCBS Arizona Medical Policy Updates »
November 2024 BCBS Arizona Medical Policy Updates:
- Ablation of Peripheral Nerves to Treat Pain
- Absorbable Nasal Implant for Treatment of Nasal Valve Collapse
- Allogenic Pancreas Transplant
- AMTAGVI (lifileucel)
- Aqueous Shunts and Stents for Glaucoma
- Autologous Chondrocyte Implantation for Forcal Articular Cartilage Lesions
- Axial Lumbosacral Interbody Fusion
- BEYFORTUS™ (nirsevimab-alip)
- Biomarker Testing in Risk Assessment and Management of Cardiovascular Disease
- Bone Morphogenetic Protein
- CABENUVA® (cabotegravir and rilpivirine) TROGARZO® (ibalizumab-uiyk)
- CABLIVI® (caplacizumab-yhdp)
- Category III Codes
- CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR LEUKEMIA AND LYMPHOMA: BREYANZI® (lisocabtagene maraleucel), KYMRIAH™ (tisagenlecleucel), TECARTUS™ (brexucabtagene autoleucel), YESCARTA™ (axicabtagene ciloleucel)
- CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR MULTIPLE MYELOMA: ABECMA® (idecabtagene vicleucel) CARVYKTI™ (ciltacabtagene autoleucel)
- Complications of Pregnancy for Plans Without Maternity Benefit
- Coverage Eligibility of Services Associated With a Cancer Clinical Trial
- Coverage Eligibility of Services Associated With a Clinical Trial For Non Grandfathered Plans
- Diagnosis and Treatment of Sacroiliac Joint Pain
- Digital Health Technologies Therapeutic Applications
- Disability Extension of Benefits
- Drug Biologic Biosimilar Wastage
- Durable Medical Equipment
- Electrical Bone Growth Stimulation of the Appendicular Skeleton
- Endoscopic Radiofrequency Ablation or Cryoablation for Barrett Esophagus
- ENJAYMO™ (sutimlimab-jome)
- EXCEPTIONS TO SELF-ADMINISTERED DRUGS
- GENE THERAPY FOR BETA THALASSEMIA AND SICKLE CELL DISEASE: CASGEVY™ (exagamglogene autotemcel), LYFGENIA™ (lovotibeglogene autotemcel), ZYNTEGLO™ (betibeglogene autotemcel)
- GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY: ELEVIDYS (delandistrogene moxeparvovec-rokl)
- GENE THERAPY FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA: VYJUVEK (beremagene geperpavec-svdt)
- GENE THERAPY FOR HEMOPHILIA B BEQVEZ™ (fidanacogene elaparvovec-dzkt) HEMGENIX® (etranacogene dezaparvovec-drlb)
- GENE THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER: ADSTILADRIN® (nadofaragene firadenovec-vncg)
- GENE THERAPY FOR SEVERE HEMOPHILIA A: ROCTAVIAN (valoctocogene roxaparvovec-rvox)
- GIVLAARI© (givosiran)
- Hearing Aids
- Hematopoietic Cell Transplantation for Autoimmune Diseases
- Hematopoietic Cell Transplantation for Central Nervous System Embryonal Tumors and Ependymoma
- Hormone Therapy
- Immunizations
- Implantable Peripheral Nerve Stimulation Device
- Intraoperative Assessment of Tissue Perfusion
- Intraoperative Neurophysiologic Monitoring
- Intraoperative Radiotherapy
- INTRAVENOUS KETAMINE INFUSION FOR TREATMENT OF OFF-LABEL INDICATIONS INCLUDING PSYCHIATRIC DISORDERS AND CHRONIC PAIN
- ISLET TRANPLANTATION FOR TYPE 1 DIABETES: LANTIDRA (donislecel-jujn)
- IZERVAY (avacincaptad pegol) SYFOVRE (pegcetacoplan)
- Laboratory Testing for Synovasure
- LeFort I Osteotomy
- LENMELDY (atidarsagene autotemcel)
- Maternal Serum Biomarkers
- Medicare Advantage Ambulance Services
- Medicare Advantage Part B Step Therapy Policy – 2024
- Medicare Advantage Part B Step Therapy Policy – 2025
- Mobile Cardiac Outpatient Telemetry
- NULIBRY™ (fosdenopterin)
- OMISIRGE® (omidubicel-onlv)
- OXLUMO® (lumasiran)
- Parenteral and Enteral Nutrition
- Percutaneous Electrical Nerve Field Stimulation for Irritable Bowel Syndrome
- Percutaneous Tibial Nerve Stimulation
- Prenatal Maternity Care for ON Semiconductor Saver HDHP
- REBYOTA™ (fecal microbiota, live-jslm) ZINPLAVA™ (bezlotoxumab)
- RYSTIGGO (rozanolixizumab-noli) VYVGART (efgartigimod alfa-fcab) VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) O1153.docx
- SAPHNELO™ (anifrolumab-fnia)
- SCENESSE® (afamelanotide)
- Sexually Transmitted Infection Testing
- Site of Service Requirements for Certain Medications
- Small Bowel,Liver and Multivisceral Transplant
- SOLIRIS® (eculizumab) ULTOMIRIS® (ravulizumab-cwvz)
- Telehealth and Non Face To Face Services
- Total Artificial Hearts and Implantable Ventricular Assist Devices
- Transanal Endoscopic Microsurgery TEMS
- Transcatheter Mital Valve Repair
- Transurethral Water Vapor Thermal Therapy and Transurethral Water Jet Ablation
- Trial Spinal Cord Stimulator Placement
- TZIELD™ (teplizumab-mzwv) IV
- UPLIZNA™ (inebilizumab-cdon)
How Does Policy Alerts Work?
Policy Alerts’ medical policy monitoring and alerts software continuously monitors Commercial, Medicare, and Medicaid coverage information to keep you up-to-date on coverage changes in real-time.
Policy Alerts’ software locates relevant Payer medical policies and coverage information from across the web. This software monitors that information for updates and changes while also searching for new medical policies and coverage information. Whenever changes occur, Policy Alerts immediately sends out an email notification containing a summary of what has changed.
Clients can access their medical policies and payer coverage summary on the interactive Policy Alerts dashboard. Never miss another important insurance carrier medical policy review or coverage decision update again!
✓ Thousands of subscribers ✓ Easy setup
Related Posts
